Financial Times: Sanofi confident dengue drug will benefit patients and investors
“…[D]rugs group Sanofi has produced the world’s first vaccine for the mosquito-borne viral disease [dengue], which it expects to launch by the end of this year. While Sanofi is championing the potential public health benefits of the vaccine, the French drugmaker is also open about its commercial ambitions. … ‘The dengue vaccine will be in the high end of profitability among our vaccines,’ says Olivier Charmeil, chief executive of Sanofi Pasteur, Sanofi’s vaccines division…” (Webber et al., 7/20).